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Abstract. Soft tissue sarcomas (STS) are a group of rare 
mesenchymal cancers that include approximately 50 histolog-
ical types and account for 1% of all adult cancers. The standard 
curative treatment option for localized disease is surgical 
resection and, if a surgically removed tumor exhibits high-risk 
characteristics, adjuvant chemotherapy and radiotherapy may 
be administered. Sarcoma presenting at an advanced stage has 
a dismal prognosis and survival has not markedly improved 
over the last 20 years. The standard first-line treatment for 
advanced STS, other than gastrointestinal stromal tumors, is 
cytotoxic chemotherapy. Therapies targeting pro-angiogenic 
factors have been a focus of drug development for STS over 
the last few years. Pazopanib, a multitargeted tyrosine kinase 
inhibitor, is a novel treatment option for patients with meta-
static STS in the second-line setting. This is a presentation of 
2 case reports of patients with metastatic STS who responded 
well to treatment with pazopanib.
Introduction
Soft tissue sarcomas (STS) are a heterogeneous group of rare 
tumors that arise from mesenchymal cells at various body 
sites (1,2). The malignant precursor cell(s) may differentiate 
along one or several lineages, such as muscle, adipose, fibrous, 
cartilage, nerve or vascular tissue. STS has >50 distinct 
histological subtypes, with leiomyosarcoma, liposarcoma, 
synovial sarcoma, undifferentiated pleomorphic sarcoma and 
malignant peripheral nerve sheath tumors being among the 
most common (3). STS occurs accounts for ~1% of malignan-
cies in adults and 2% of the overall cancer mortality (4,5). 
Approximately half of the patients diagnosed with STS 
present with advanced̸metastatic  cancer and eventually 
succumb to their disease (1,6). The median overall survival for 
advanced-stage disease was reported to range between 11 and 
18 months (7,8).
For advanced-stage STS, judicious use of cytotoxic therapy 
provides meaningful palliation and may prolong survival. The 
selection of systemic therapy may be individualized based 
upon several factors, including tumor histology, health status 
and preferences of the patients (2,8,9). The European Society 
for Medical Oncology and the National Comprehensive 
Cancer Network treatment guidelines recommend anthra-
cycline-based chemotherapy, primarily with doxorubicin, 
either as monotherapy or in combination with ifosfamide, as 
first-line treatment for the most advanced STS subtypes (9,10). 
Pazopanib is a novel treatment modality and has been approved 
by the Food and Drug Administration and the European 
Medicines Agency as second-line treatment after a phase III 
trial of this drug reported a statistically significant increase 
in progression-free survival. Of note, only 6% of the patients 
exhibit a tumor response and in the majority of the cases, 
stable disease may be achieved. There remains the question of 
whether this drug may be used in highly symptomatic cases, 
as in some cases response rate may be a more important goal 
than survival benefit. In this study, we present 2 case reports of 
patients with STS who achieved a nearly complete radiological 
response to pazopanib.
Case 1
A 25-year-old female patient presented with a soft tissue mass 
at the level of right knee that had developed 3 years prior. The 
patient's past history was negative for systemic diseases and 
the laboratory evaluation was normal. We used positron emis-
sion tomography (PET)-computed tomography (CT) for initial 
staging and to exclude systemic metastases. The PET-CT 
showed a hypermetabolic lesion close to the right knee joint, 
filling the popliteal area, sized 110x82x160 mm (maximum 
standard uptake value, 10.7) (Fig. 1). The histopathological 
evaluation was compatible with a malignant mesenchymal 
tumor, namely a synovial sarcoma. The patient was treated 
with systemic neoadjuvant chemotherapy, followed by surgical 
resection in August, 2010. The patient also received adjuvant 
radiotherapy.
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In September, 2012, the patient presented with dyspnea and 
her detailed evaluation with PET-CT revealed lung metastases, 
accompanied by right iliac chain and right inguinal lymph-
adenopathy (Fig. 2). The patient received treatment with a 
gemcitabine-docetaxel combination regimen, but the disease 
progressed. Subsequently, pazopanib (800 mg/day) was initi-
ated in January, 2013. The radiological evaluation in July, 2013 
was compatible with nearly complete response (Figs. 3).
Case 2
A 50-year-old female patient presented with a right breast 
mass in July, 2010. The preoperative biopsy was compatible 
with the diagnosis of primary breast leiomyosarcoma and a 
right mastectomy was performed. The patient was treated with 
6 courses of doxorubicin-based adjuvant chemotherapy. During 
surveillance, the patient presented with progressive dyspnea 
in September, 2012 and the PET-CT scan revealed lytic bone 
lesions and hypermetabolic metastatic lung nodules (Fig. 4). 
At the second-line setting, the patient was treated with 
docetaxel-gemcitabine and the progression-free survival 
with this regimen was 6 months; the maximal response, as 
evaluated by PET-CT, was stable disease. The patient received 
Figure 1. Case 1: Positron emission tomography-computed tomography 
showing a primary hypermetabolic lesion, sized 110x82x160 mm (maximum 
standard uptake value, 10.7), filling the entire popliteal fossa.
Fıgure 2. Case 1: Positron emission tomography-computed tomography 
revealed multiple hypermetabolic nodular lesions compatible with lung 
metastases.
Figure 3. Case 1: Computed tomography evaluation following treatment with 
pazopanib revealed a good partial response.
Figure 4. Case 1: Computed tomography evaluation following treatment with 
pazopanib revealed a good partial response.
Figure 5. Case 2: Computed tomography evaluation demonstrating hyper-
metabolic osteolytic bone lesions and multiple metastatic lung nodules.
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palliative radiotherapy to the bone metastases in March, 2013. 
The radiological evaluation following radiotherapy showed 
progression of the lung metastases. Subsequently, pazopanib 
(800 mg/day) was initiated in May, 2013. The radiological 
evaluation in July, 2013 was compatible with nearly complete 
response (Fig. 5).
Discussion
Metastatic STS is an incurable disease and very little improve-
ment regarding the treatment of advanced STS has been 
achieved over the last 2 decades, excluding imatinib treatment 
for gastrointestinal stromal tumors (GIST). Pazopanib, which 
is a synthetic indazolpyrimidine, is a multitargeted tyrosine 
kinase inhibitor, exhibiting activity against the vascular endo-
thelial growth factor receptors 1, 2 and 3, and the platelet-derived 
growth factor receptor (11). Single-agent pazopanib was found 
to be effective against various STS subtypes in a phase II 
clinical trial (12). Subsequently, a registration phase III 
study (PALETTE trial) was designed to compare pazopanib 
(800 mg daily) vs. placebo in 369 patients with a variety of 
histological subtypes, excluding liposarcomas or GIST, in the 
second-line setting (13). There was a statistically significant 
increase in PFS in the pazopanib group (4.6 vs. 1.6 months) 
and the survival benefit was consistent across all histological 
subtypes (14). However, although pazopanib significantly 
increased PFS in that study, the objective response rate was 
quite low and the best overall response was partial response 
in 6% of the pazopanib group. When evaluating pazopanib in 
the light of those trials, we may not recommend pazopanib 
for patients in need of fast symptomatic relief. However, when 
we used pazopanib in our first 2 cases as third-line treatment, 
a nearly complete response was achieved. On analyzing the 
demographic, clinical and histopathological characteristics 
of these 2 cases, including drug-related side effects, we were 
unable to identify a common point that may help explain why 
these 2 patients exhibited such a strong response to pazopanib.
In conclusion, we reported 2 cases that exhibited an unex-
pected, nearly complete response to anti-angiogenic treatment, 
with the aim to raise the question of whether we can define a 
specific group of patients who respond well to treatment with 
pazopanib.
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